DOSE OF REALITY: NEW ANALYSIS UNDERSCORES HOW OFTEN BIG PHARMA’S PATENTS ARE UNRELATED TO CLINICAL INNOVATION
Study Finds Just Six Percent of Drug Patents in Infringement Suits Were for… Read More
Study Finds Just Six Percent of Drug Patents in Infringement Suits Were for… Read More
Biogen Decision to Change Aduhelm Price After Public Outcry Demonstrates Big… Read More
Brand Name Drug Companies’ Business-as-Usual Approach to Price Increases… Read More
Part I: Price-Gouging An Unproven Treatment, Setting Out-of-Control Launch… Read More
Part II: Pushing Debunked Innovation Rhetoric to Oppose Rx Solutions Despite… Read More
Part III: Big Pharma Maintains Price-Hiking, Patent-Gaming Business-As-Usual… Read More
Investigation Finds Big Pharma Hiked Prices More Than 250 Times On Just 12 Top… Read More
New PhRMA Ad Campaign Aims to Dodge Accountability, Push Pharma-Backed Rebate… Read More
New Analysis Underscores How Big Pharma’s Price Increases Cost The American… Read More
AstraZeneca’s Q3 Earnings Report Shows Pandemic Price Hikes Profitable for… Read More
New Round of Q3 Earnings Reports Continue to Show Big Pharma Profits Buoyed By… Read More
New Analysis Highlights How Big Pharma Uses Limitless Resources… Read More